Organization
Guangdong Ruishun Biotech
4 clinical trials
7 abstracts
Clinical trial
A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus ErythematosusStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)Status: Not yet recruiting, Estimated PCD: 2025-05-20
Clinical trial
A Single-arm, Single/Multiple Dose-escalation and Dose-extension Phase I Clinical Trial of RC1012 Injection (Allogeneic DNT Cells) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I/II Clinical Trial of RC1012 Injection for the Prevention of Relapse in AML Patients After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-05-27
Abstract
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,
Abstract
Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
Magnetic resonance imaging tumor regression shrinkage patterns during neoadjuvant chemotherapy versus neoadjuvant immunochemotherapy in triple-negative breast cancer (NeoMDSS-TN-SP): A nonrandomized, prospective cohort study.Org: Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou JOYO Pharma,
Abstract
Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen.Org: The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, SYSU, Guangzhou JOYO Pharma, Guangdong Ruishun Biotech,
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou JOYO Pharma, Guangdong Ruishun Biotech, China National Biotec Group,
Abstract
A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.Org: Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Provincial Hospital of Chinese Medicine Breast Center, Guangdong Provincial People's Hospital,